433 related articles for article (PubMed ID: 26504378)
1. A longitudinal, retrospective cohort study on the impact of roflumilast on exacerbations and economic burden among chronic obstructive pulmonary disease patients in the real world.
Wan Y; Sun SX; Corman S; Huang X; Gao X; Shorr AF
Int J Chron Obstruct Pulmon Dis; 2015; 10():2127-36. PubMed ID: 26504378
[TBL] [Abstract][Full Text] [Related]
2. Impact of roflumilast on exacerbations of COPD, health care utilization, and costs in a predominantly elderly Medicare Advantage population.
Moll K; Sun SX; Ellis JJ; Howe A; Amin A
Int J Chron Obstruct Pulmon Dis; 2015; 10():565-76. PubMed ID: 25834417
[TBL] [Abstract][Full Text] [Related]
3. Roflumilast: Who Is Using It and How It Affects Health Care Resource Utilization and Costs.
Jain R; Cai Q; Sun SX; Tan H
Manag Care; 2015 Aug; 24(8):40-8. PubMed ID: 26399141
[TBL] [Abstract][Full Text] [Related]
4. A 1-year prospective cost-effectiveness analysis of roflumilast for the treatment of patients with severe chronic obstructive pulmonary disease.
Rutten-van Mölken MP; van Nooten FE; Lindemann M; Caeser M; Calverley PM
Pharmacoeconomics; 2007; 25(8):695-711. PubMed ID: 17640111
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of roflumilast in combination with bronchodilator therapies in patients with severe and very severe COPD in Switzerland.
Samyshkin Y; Schlunegger M; Haefliger S; Ledderhose S; Radford M
Int J Chron Obstruct Pulmon Dis; 2013; 8():79-87. PubMed ID: 23386787
[TBL] [Abstract][Full Text] [Related]
6. [Roflumilast in combination with long-acting bronchodilators in the management of patients with severe and very severe COPD. A cost-effectiveness analysis for Germany].
Nowak D; Ehlken B; Kotchie R; Wecht S; Magnussen H
Dtsch Med Wochenschr; 2013 Jan; 138(4):119-25. PubMed ID: 23322425
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of roflumilast as an add-on treatment to long-acting bronchodilators in the treatment of COPD associated with chronic bronchitis in the United Kingdom.
Samyshkin Y; Kotchie RW; Mörk AC; Briggs AH; Bateman ED
Eur J Health Econ; 2014 Jan; 15(1):69-82. PubMed ID: 23392624
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of roflumilast as an add-on to triple inhaled therapy vs triple inhaled therapy in patients with severe and very severe COPD associated with chronic bronchitis in the UK.
Kiff C; Ruiz S; Varol N; Gibson D; Davies A; Purkayastha D
Int J Chron Obstruct Pulmon Dis; 2018; 13():2707-2720. PubMed ID: 30214188
[TBL] [Abstract][Full Text] [Related]
9. Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial.
Martinez FJ; Calverley PM; Goehring UM; Brose M; Fabbri LM; Rabe KF
Lancet; 2015 Mar; 385(9971):857-66. PubMed ID: 25684586
[TBL] [Abstract][Full Text] [Related]
10. Roflumilast: a phosphodiesterase-4 inhibitor for the treatment of severe chronic obstructive pulmonary disease.
Pinner NA; Hamilton LA; Hughes A
Clin Ther; 2012 Jan; 34(1):56-66. PubMed ID: 22284994
[TBL] [Abstract][Full Text] [Related]
11. Lower 30-day readmission rates with roflumilast treatment among patients hospitalized for chronic obstructive pulmonary disease.
Fu AZ; Sun SX; Huang X; Amin AN
Int J Chron Obstruct Pulmon Dis; 2015; 10():909-15. PubMed ID: 25999706
[TBL] [Abstract][Full Text] [Related]
12. Roflumilast added to triple therapy in patients with severe COPD: a real life study.
Muñoz-Esquerre M; Diez-Ferrer M; Montón C; Pomares X; López-Sánchez M; Huertas D; Manresa F; Dorca J; Santos S
Pulm Pharmacol Ther; 2015 Feb; 30():16-21. PubMed ID: 25445930
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness analysis of roflumilast/tiotropium therapy versus tiotropium monotherapy for treating severe-to-very severe COPD.
Sun SX; Marynchenko M; Banerjee R; Cheng D; Mocarski M; Yin D; Yu AP; Wu EQ
J Med Econ; 2011; 14(6):805-15. PubMed ID: 21992217
[TBL] [Abstract][Full Text] [Related]
14. Does roflumilast decrease exacerbations in severe COPD patients not controlled by inhaled combination therapy? The REACT study protocol.
Calverley PM; Martinez FJ; Fabbri LM; Goehring UM; Rabe KF
Int J Chron Obstruct Pulmon Dis; 2012; 7():375-82. PubMed ID: 22791991
[TBL] [Abstract][Full Text] [Related]
15. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials.
Calverley PM; Rabe KF; Goehring UM; Kristiansen S; Fabbri LM; Martinez FJ;
Lancet; 2009 Aug; 374(9691):685-94. PubMed ID: 19716960
[TBL] [Abstract][Full Text] [Related]
16. Roflumilast in the management of chronic obstructive pulmonary disease.
Lipari M; Benipal H; Kale-Pradhan P
Am J Health Syst Pharm; 2013 Dec; 70(23):2087-95. PubMed ID: 24249758
[TBL] [Abstract][Full Text] [Related]
17. Roflumilast: doubtful efficacy but clear harms in COPD.
Prescrire Int; 2013 Jan; 22(134):5-9. PubMed ID: 23367674
[TBL] [Abstract][Full Text] [Related]
18. Roflumilast: a novel treatment for chronic obstructive pulmonary disease.
Reid DJ; Pham NT
Ann Pharmacother; 2012 Apr; 46(4):521-9. PubMed ID: 22433610
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of roflumilast in the COPD frequent exacerbator phenotype.
Wedzicha JA; Rabe KF; Martinez FJ; Bredenbröker D; Brose M; Goehring UM; Calverley PMA
Chest; 2013 May; 143(5):1302-1311. PubMed ID: 23117188
[TBL] [Abstract][Full Text] [Related]
20. Clinical Question: In adults with COPD does roflumilast reduce the frequency of exacerbations compDared to standard therapies aIone?
Huser JM; Hodgden JD
J Okla State Med Assoc; 2016 Feb; 109(2):59-60. PubMed ID: 27169222
[No Abstract] [Full Text] [Related]
[Next] [New Search]
